New EU legal measures, which entered into force this month, will see three harmful new psychoactive substances (NPS) brought under control across the EU. The substances — all new synthetic cathinones — are: 2-methylmethcathinone (2-MMC), 4-bromomethcathinone (4-BMC) and N-ethylnorpentedrone (NEP). These are now classified as controlled ‘drugs’ under EU law.
The decision to control the substances was introduced by the European Commission last year through a Delegated Directive, amending the existing legal framework designed to bring a stronger and faster response to NPS in Europe (1). The…
Čtěte více
This month, the EUDA assumed the year-long presidency of the EU Justice and Home Affairs Agencies’ Network (JHAAN), which is composed of nine agencies: CEPOL, EIGE, EUAA, EUDA, EU-LISA, EUROJUST, EUROPOL, FRA and FRONTEX. The presidency theme, ‘One Safety — building preparedness and resilient communities’, promotes a cross-sector integrated approach to building a safer, fairer and…
Čtěte více
Effective drug monitoring in Europe depends on strong cooperation with Member States. In a new publication out today, we outline the key features of the Reitox Alliance, a new partnership framework between the EUDA and the national focal points (NFPs) of the Reitox network. The publication (Reitox Alliance operating framework) sets out the scope of the Alliance, the partners involved, its core tasks and governance arrangements.
Adopted by our Management Board in December 2025, the Reitox Alliance replaces the previous Reitox operating framework (in place since 2003) and aligns the…
Čtěte více
This month, Cyprus assumed the rotating Presidency of the Council of the European Union, under the overarching motto ‘An Autonomous Union. Open to the World’. The motto reflects a forward-looking approach that combines internal strength and independence with openness, cooperation and global engagement.
The Cyprus Presidency is guided by five broad priorities:
Autonomy through security, defence readiness and preparedness;
Autonomy through competitiveness;
Open to the world and autonomous;
An autonomous Union of values that leaves no one behind; and
A long-term budget for an autonomous Union…
Čtěte více
The European Commission has published the Horizon Europe Work Programmes for 2026–2027, confirming EUR 14 billion in EU investment to support research and innovation across Europe over the next two years. In line with the EUDA mandate (1), we have reviewed the programmes and identified a set of upcoming Horizon Europe calls of relevance to drug-related research and innovation. These calls span multiple parts of the programme, including:
Cluster 1: Health — addressing prevention, mental health, non-communicable diseases and health systems.
Cluster 3: Civil Security for Society — including…
Čtěte více
This week, the European Union Drugs Agency (EUDA) welcomes its new Executive Director Dr Lorraine Nolan (Ireland), as she begins a five-year term leading the agency.
Dr Nolan was elected to the position by the EUDA Management Board in June 2025, following a competitive public recruitment process launched in September 2024.
Dr Nolan brings over 25 years of senior leadership experience across science, public service and regulatory affairs, including 10 years as Chief Executive of Ireland’s Health Products Regulatory Authority (HPRA). Her career spans national, European and international roles…
Čtěte více
